Lipid droplets, potential biomarker and metabolic target in glioblastoma.
Lipid droplets, potential biomarker and metabolic target in glioblastoma.
复制标题
DOI：
10.18103/imr.v3i5.443
复制
发表时间：
2017-05
期刊：
影响因子：
--
通讯作者：
Guo D
中科院分区：
文献类型：
--
作者：
Geng F;Guo D
脂滴（LD）是储存大量中性脂质、甘油三酯（TG）和/或胆固醇酯（CE）的亚细胞器。LD通常在脂肪细胞、肝细胞和巨噬细胞中形成，并且它们的形成已显示与代谢疾病的进展相关，即，肥胖、脂肪肝和动脉粥样硬化。有趣的是，在一些肿瘤组织中也发现了LD。我们最近发现，LD在胶质母细胞瘤（GBM）中普遍存在，这是最致命的脑肿瘤，但在低级别胶质瘤和正常脑组织中检测不到，这表明LD可能作为GBM的一种新的诊断生物标志物。这篇简短的综述将简要介绍LD生物学，总结最近的观察LD在几种类型的癌症组织，并讨论LD在GBM的形成。此外，我们将强调SOAT 1（甾醇-O转移酶1），一个关键酶调节CE合成和LD形成GBM中，在调节SREBP（甾醇调节元件结合蛋白）激活的作用。LD和SOAT 1的治疗潜力将被讨论。
Lipid droplets (LDs) are subcellular organelles that store large amounts of the neutral lipids, triglycerides (TG) and/or cholesteryl esters (CE). LDs are commonly formed in adipocytes, liver cells and macrophages, and their formation has been shown to be associated with the progression of metabolic diseases, i.e., obesity, fatty liver and atherosclerosis. Interestingly, LDs are also found in some tumor tissues. We recently showed that LDs are prevalent in glioblastoma (GBM), the most deadly brain tumor, but are not detectable in low-grade gliomas and normal brain tissues, suggesting that LDs may serve as a novel diagnostic biomarker for GBM. This short review will briefly introduce LD biology, summarize recent observations about LDs in several types of cancer tissues, and discuss LD formation in GBM. Moreover, we will highlight the role of SOAT1 (sterol-O transferase 1), a key enzyme regulating CE synthesis and LD formation in GBM, in the regulation of SREBP (sterol regulatory-element binding protein) activation. The therapeutic potential of LDs and SOAT1 will be discussed.